Why physician oversight matters at a med spa
Medically reviewed by
The LovMedSpa medical team, led by Dr. Ahmed Elsoury, MD and Dr. Mark Ennett, MD
Last reviewed: June 2026
Physician oversight in a med spa is a clinical function, not a marketing label. Botulinum toxin type A — the active ingredient in neuromodulators like Botox, Dysport, and Xeomin — is an FDA-approved prescription drug; dermal fillers are FDA-cleared Class III medical devices, the same regulatory tier as implanted cardiac devices; energy platforms like radiofrequency microneedling and CO₂ lasers deliver controlled thermal injury to tissue at parameters that determine both the result and the risk. These are medical procedures. A physician medical director who is actively involved sets the protocols that govern who gets treated, at what parameters, and what happens when a decision requires authority that is, by definition, the practice of medicine.
What these procedures actually are — the regulatory and clinical reality
The phrase "cosmetic treatment" understates the mechanism of what is happening. Botulinum toxin works through chemodenervation — it blocks acetylcholine release at the neuromuscular junction, preventing the muscle contraction that drives dynamic rhytids (expression lines). It is a schedule-regulated prescription drug in every U.S. state; no med spa can legally purchase or administer it without a physician in the prescribing chain. Hyaluronic acid fillers are Class III medical devices — the FDA's highest-risk device classification, reserved for devices that support or sustain life or present a potential unreasonable risk of illness or injury. Energy devices operate differently but carry the same clinical weight: a fractional CO₂ laser ablates tissue through controlled vaporization; an RF microneedling device deposits thermal energy into the reticular dermis at temperatures of 55–65°C to trigger a wound-healing cascade. The settings that determine efficacy and the settings that determine safety are the same settings — and calibrating them correctly for a specific patient requires clinical knowledge, not technician training.
What a medical director actually does — protocols, prescribing, accountability
An active medical director designs and enforces the treatment protocols that govern every appointment: which devices operate at what energy parameters for which patient profiles, what contraindications disqualify a patient from a given treatment, what medications require dose adjustments or timing changes. They hold the prescribing authority for the prescription drugs used in the practice — botulinum toxin, topical anesthetics requiring physician sign-off, GLP-1 receptor agonists like semaglutide and tirzepatide in weight management programs. They review medical histories for flags that a non-physician might not recognize as clinically relevant. And they are the accountable clinician when a decision exceeds the scope of the treating provider: ordering hyaluronidase for a filler complication, determining whether a patient's post-treatment presentation requires emergency escalation, or adjusting a protocol when a patient's response deviates from the expected range. The gap between active and nominal oversight is concrete: a physician who wrote the protocols and knows the patients is categorically different from one who signed a compliance contract and has never been to the location.
Candidacy screening — where oversight is most consequential
The most consequential work of physician oversight happens before anything is injected or treated — in the medical history review that determines whether a patient is an appropriate candidate. A few examples of what that screening catches. Isotretinoin (commonly known by the brand name Accutane): current use or use within 6 months contraindicates most energy device treatments because the medication alters sebaceous gland function and skin fragility in ways that increase wound-healing complications. Aminoglycosides (a class of antibiotics including gentamicin): this drug class potentiates botulinum toxin, meaning a patient on aminoglycosides may experience unexpectedly stronger neuromuscular blockade — a clinical interaction that changes both dosing and outcome. Active herpes simplex near the treatment site requires antiviral prophylaxis before energy treatments; skipping this step can trigger an outbreak. Autoimmune conditions and immunosuppressant medications affect candidacy for biostimulators and some energy treatments in ways that require individual clinical judgment. The adverse events that physician-reviewed screening prevents are the ones that never make it into a patient's experience — because the provider who caught them before treatment never let them happen.
Common questions
Does botulinum toxin have to be prescribed by a physician?
In most U.S. states, yes — botulinum toxin type A is a prescription drug, meaning a licensed physician must be in the prescribing chain. The practical implementation varies by state: in some, an NP or PA can prescribe independently within their scope; in others, the physician must prescribe directly. Any med spa administering botulinum toxin without a physician in the oversight chain is operating outside regulatory requirements, regardless of how the service is marketed.
What's the risk of getting injectables somewhere without real physician oversight?
The risk doesn't concentrate in routine appointments — most filler and tox sessions are uneventful regardless of setting. It concentrates in edge cases: a contraindicated patient missed in screening, a complication not recognized early enough, a medication interaction that changes an outcome in ways a non-physician didn't anticipate. The absence of physician oversight doesn't make every appointment dangerous; it removes the layer that catches the cases that would otherwise be.
How is a physician-led med spa different from one where a physician is 'on call'?
A physician who is on-call for a practice they don't work in has no familiarity with the patients, no involvement in the protocols, and no ability to respond in the minutes that matter in a time-critical complication. Active physician oversight means the MD designed the protocols, reviews the screening criteria, and is reachable in a clinical sense — not just listed for compliance. The relevant test: if a serious complication happened right now, what would happen in the first ten minutes?
At LovMedSpa, treatment protocols are designed and maintained under the active oversight of medical director Dr. Ahmed Elsoury, MD (New York and Connecticut) and Dr. Mark Ennett, MD (South Florida) — with pre-treatment clinical assessments, on-site hyaluronidase, and physician-reviewed candidacy screening at every location across Brooklyn, Manhattan, Staten Island, Aventura, and West Farms. A consultation is the right place to ask about protocols, credentials, and what oversight looks like in practice.
This is general information, not medical advice; treatment candidacy and protocol decisions are determined by a licensed provider at consultation.